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ABSTRACT 
 
Phoslactomycins (PLMs) are a group of natural products belonging to a polyketides class. 
These polyketides are synthesized by sequential reaction catalyzed by a collection of 
enzymes activities called polyketide synthases. A polyketide is a large class of diverse 
compounds that are characterized by more than two carbonyl groups connected by single 
intervening carbon atoms. In other words, a polyketide is a polymer whose monomer is a 
ketide. The PLMs are also known as phosphazomycins or phospholines. These compounds 
were isolated based on antifungal and antitumor activities. This array of promising 
biological activities has stimulated research into the field of PLMs for treatment of various 
diseases such as aspergillosis. A significant success has been reported in understanding and 
manipulating PLM biosynthesis. However, its post-polyketide biosynthetic mechanism 
remains to be elucidated. In this study, we established steps needed to pave the way for the 
elucidation of the post-polyketide synthase tailoring steps in the phoslactomycin 
biosynthetic pathway. Various, biological activities of polyketide natural products are often 
linked with specific structural motifs, biosynthetically introduced after construction of the 
polyketide core. Therefore, investigation of such “post-polyketide synthase (PKS)” 
modifications is important, and the accumulated knowledge on these processes can be 
applied for combinatorial biosynthesis to generate new polyketide derivatives with 
enhanced biological activity. 
In this study, the enzymes and genes responsible for the modification of the 
phoslactomycin moiety have been investigated to verify their functions and to study how 
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they are coordinated to achieve the desired phoslactomycin. The proposed modification 
steps in the PLM biosynthesis pathway involves, PlmT4 a cytochrome P450 
monooxygenase, PlmT5, a kinase, and PlmT8 an oxidoreductase. These enzymes were 
successfully cloned, overexpressed, and purified from an overexpression vector. Mutant 
strains for two genes plmT4 and plmT8 were either constructed or studied. The function of 
PlmT4 tailoring enzyme was characterized, by gene disruption and an in vitro enzyme 
activity assay. The isolation of PLM 1 an intermediate analog from plmT4 mutant strain 
and the observation of a malonylated PLMs, suggests that the malonyl side chain is 
introduced during polyketide chain formation These results, will pave the way to delineate 
the intermediary steps between the PLM PKS product(s) that is released from the PLM 
PKS and the formation of the final phoslactomycin. 
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CHAPTER 1. INTRODUCTION 
 
1.1 BACKGROUND 
 
The discovery of penicillin in the 1920s followed by its successful application to treat 
infectious diseases, brought a lot of interest in finding new antibiotics from natural products 
1, 2. Meaningful progress has been made in both academia and industry leading to the 
isolation of thousands of novel natural products from a variety of sources including plants, 
insects, bacteria, fungi, and marine organisms3,4. However, serious infections caused by 
bacteria that have become resistant to commonly used antibiotic have become one of the 
most serious healthcare problems in the 21st century1. The emerging drug resistant 
pathogens demands novel antibiotics classes to be developed5. Among many natural 
products, polyketides are not only the most promising ones for developing new antibiotic 
leads, but also exhibit unusually high therapeutic value ranging from clinical use as 
anticancer, antiviral, and immunosuppressant drugs6,7. Figure 1 shows a representative of 
polyketide natural products that possess pharmacologically useful properties and have 
clinical uses.  
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Figure 1. Examples of some commonly used polyketide derived antibiotics 
 
1.2 POLYKETIDES  
 
Polyketides, isolated mostly from bacterial and fungal species, comprises one of the most 
structurally diverse classes of natural products whose scaffolds include macrolides, 
polyethers, enediynes, polyphenols, and others8, 9. Polyketides are produced as secondary 
metabolites and they display a wide range of pharmaceutical properties10. Figure 1 shows 
examples of polyketides that have therapeutic value such as rapamycin, an 
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immunosuppressant, lovastatin, a cholesterol lowering agent and resveratrol, a 
chemopreventive. Since their discovery, a number of polyketides have been clinically 
approved as drugs, in fact polyketide-derived pharmaceuticals comprise 20% of the top-
selling drugs in the world11, 12. There are 10,000 known natural polyketides, and about 1% 
has useful biological activities11. There is a tremendous interest in discovering new of 
polyketide with improved or novel pharmacological properties. Synthetic organic 
chemistry, molecular genetics and biochemistry are common routes utilized to access or 
obtain new analogues. However, synthesis of polyketides remains problematic, due to the 
structural complexity of polyketides with many functional group and stereo chemical 
centers6. Polyketides can also be difficult to isolate naturally since the producing organisms 
are often hard to culture and produce low yields6, 12. However, significant advances in 
microbial genetics and biochemistry during the past decades has permitted a better 
understanding of  the functions of  genes involved in polyketide biosynthesis13. 
Understanding the pathway provides the necessary knowledge for manipulating these 
natural enzyme systems to produce novel metabolites.  
1.3 BIOSYNTHESIS OF THE POLYKETIDE BACKBONE 
 
Polyketides are assembled by enzymes known as polyketide synthases14. Polyketides 
synthases (PKSs) are currently classified into three broad types based on the protein 
architecture and biosynthetic schemes14. These are type 1, type 11 and type 11115. The ﬁrst 
reports of bacterial type I PKS was in 1990, for type II PKS was in 1984 and type III PKS 
in 199916. Type I PKS are large multifunctional enzymes, which are organized into 
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modules15. Modular PKS are demonstrated by 6-deoxyerythromycin B synthase (DEBS) 
16 for the biosynthesis of reduced polyketides such as erythromycin as seen in Figure 2 17.  
Each separate module contains three domains to catalyze one cycle of chain extension, 
ketosynthase (KS), acyltransferase (AT), and acyl carrier protein (ACP). Some modules 
carry variable domains, such as ketoreductase (KR), dehydratase (DH) and enoylreductase 
(ER), which are responsible for keto group modification18. Type II PKS are discrete 
dissociable proteins which only own one enzymatic activity or domain, respectively14. The 
discrete proteins work synergistically and can be used iteratively, thus the final product 
cannot be predicted. Type III PKS are simple homodimers of ketosynthases which catalyze 
the condensation of one to several molecules of extender substrate onto a starter substrate 
iteratively13, 18. Bacterial and fungal PKS genes have been found to exist as gene clusters19. 
The chemistry associated with PKSs is closely related to that of the well-studied fatty acid 
synthases (FASs)19. Polyketide  biosynthesis overlaps with fatty acid synthesis not only in 
terms of mechanistic details involved in chain elongation process but also in that both the 
utilize common precursors such as acetyl coenzyme A (CoA), and malonyl CoA 20. 
Products synthesized by various types of PKSs can undergo different sets of post-PKS 
modifications by decorative enzymes encoded in the biosynthetic pathway21, 22. 
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Figure 2. Structural organization of a bacterial type 1 PKS 
 
1.4 POST-PKS MODIFICATIONS AND SIGNIFICANCE OF POST-PKS 
MODIFICATIONS 
 
The formation of a biologically active polyketide requires that fully condensed products of 
PKS catalyzed reactions usually undergo a series of tailoring events known as post-PKS 
events such as glycosylation, methylation, oxidation, reduction, and halogenation23. Such 
tailoring can enormously change the pharmacological properties of the parent polyketides, 
impacting factors such as solubility or receptor binding ability of the modified parent 
compound24. Post-PKS modification has been the subject of intense investigations over the 
past two decades and proved as a rich source of intriguing and unprecedented enzyme 
chemistries. As mentioned earlier, these post-PKS events usually result in the conversion 
of a biologically non-active polyketide into an active product25. For example, Figure 3 
showing the conversion of inactive 6-deoxyerythronolide B, to potent antibacterial agent, 
erythromycin A.  
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Erythromycin A is synthesized in two phases. ability to manipulate natural.The first phase 
involves the PKS portion of the molecule, and the second is post polyketide  
synthase “tailoring”. The systems to produce novel metabolites rests largely on increased 
mechanistic understanding of how these molecules are generated in the first and second 
phase.  
 
 
Figure 3. Post-tailoring steps leading to formation of erythromycin 
Tailoring enzymes such as oxidoreductases, group transferases, halogenases,  and 
deoxysugar biosynthetic enzymes have been largely used to generate modified polyketides, 
occasionally with improved pharmacological properties8. The overall objective of this work 
was to focus on initial post-PKS modifications involved in the biosynthesis of 
phoslactomycin polyketide. 
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1.5 PHOSLACTOMYCIN BIOSYTHESIS  
 
Phoslactomycins (PLMs) are polyketide natural products and are produced by several 
Streptomyces species. Streptomyces sp. HK803 is reported to produce six analogues of 
phoslactomycin (Plm A through F), shown in Figure 4 23. PLMs were isolated based on 
their potent antifungal activities. The protein phosphatase 2A (PP2A) inhibition is believed 
to be the mechanism of action and the basis for this antifungal activity26. A significant 
success has been reported in understanding and manipulating PLM biosynthesis. The 
biosynthesis of PLMs is catalyzed by modular polyketide synthase as shown in Figure 5. 
It has been reported and verified that it uses cyclohexanecarboxylic acid (CHC) as a starter 
unit27. However, some of the biosynthesis steps of the post-polyketide synthase tailoring 
steps of PLMs remain to be elucidated.  
The gene cluster for phoslactomycin has been cloned and characterized. The sequence 
analysis revealed a 75kb region containing 29 open reading frames that appear to be 
associated with PLM biosynthesis28. Enzymes proposed to be involved in post polyketide 
modification studied so far are, PlmT2, PlmS3 and PlmS2. This work has led to the 
discoveries that the ∆2, 3 double bond of the unsaturated lactone  is established by a post 
tailoring enzyme PlmT2
21. This is because the mutant strain named NP7 (plmT2∆plmS2) 
was shown to produce C-3 malonylated PLM B (M-PLM B)  The enzyme PlmT2 is thought 
to catalyze an unprecedented decarboxylative elimination reaction in the PLM intermediate 
with a malonylated group at C-3 as shown in Figure 6 , even though up to this date it 
remains to be determined at which stage the decarboxylation occurs21. This observation 
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demonstrates that all modification steps which occur to the PLM core structure can occur 
with a C-3 malonyl ester.  Thus it is possible to observe malonylation as we study the post 
polyketide synthase -tailoring steps in the PLM biosynthetic pathway. 
 
 
Figure 4. Structure of Phoslactomycin 
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Figure 5. Type 1 Phoslactomycin PKS 
 
 
 
 
 
 
 
Figure 6. Possible role for PlmT2 in catalyzing a decarboxylative elimination 
 
Studies on the biosynthetic pathway of Streptomyces pulveraceus which produces 
fostriecin antibiotics which are structurally related to PLMs also indicated that malonylated 
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polyketide formation could be a normal biosynthetic process in the formation of 
unsaturated lactone in fostriecin25. Studies on other post-polyketide synthase tailoring 
enzymes involved in the PLM pathway, PlmS2 and PlmS3 also revealed some information 
regarding post polyketide synthase tailoring steps. A mutant strain of the gene,  plmS2, 
resulted in a mutant (NP2) that only produced PLM B29. Additionally, the plmS2 open 
reading frame (ORF) was expressed as an N-terminally polyhistidine-tagged protein in 
Streptomyces coelicolor and the purified protein has been shown to catalyze conversion of 
PLM B to PLM G as shown in Figure 729 . Data obtained demonstrated that PlmS2, a 
cytochrome P-450 monooxygenase (CYPs), is responsible for catalyzing hydroxylation at 
C-18 of the PLM B as shown in Figure 7. F). The plmS3 gene was identified as the 
acyltransferase responsible for C-18 acylation of PLM G13  . This was confirmed by 
generation of a plmS3 deletion mutant that resulted in selective production of PLM G, 
supporting the proposed role of this gene product. The 921-bp plmS3 ORF was cloned and 
expressed as an N-terminally polyhistidine-tagged protein in E.coli, and the recombinant 
purified protein was shown to catalyze acylation of PLM G with isobutyryl-CoA, 3-
methylbutyryl-CoA and cyclohexyl-carbonyl-CoA to give PLM A, PLM C and PLM E 
respectively, also confirming the role of plmS3 gene product13. 
This work will focus on studying other post-polyketide synthase tailoring genes, plmT4 
(cytochrome P450 monooxygenase), plmT5 (a kinase), and plmT8 (oxidoreductase). Figure 
9 shows the focus for this work, it is noteworthy that the introduction of amine precedes a 
reaction by an oxidoreductase, to form an aldehyde that will then be converted to an amine 
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by a proposed aminotransferase PlmT1. This project will pave the way towards deciphering 
the post polyketide synthase tailoring steps in the phoslactomycin biosynthesis pathway. 
 
 
 
Figure 7. The last two steps of the phoslactomycin biosynthetic pathway 
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Figure 8. The proposed post-polyketide tailoring steps in the phoslactomycin 
biosynthetic pathway, studied for this project 
 
 
 
 
 
 
 
 
C-9 (Phosphorylation) 
 C-8 (hydroxylation) 
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CHAPTER 2. ISOLATION AND PARTIAL CHARACTERIZATION OF PLM 1  
 
2.0 INTRODUCTION 
 
In nature phoslactomycins are synthesized by modular PLM polyketide synthases and then 
modified by post-PKS enzymes28, 29. As mentioned earlier, the PLM gene cluster has been 
cloned and on the basis of predicted functions for each post-PKS gene inferred from 
sequence similarities, it was proposed that the post tailoring steps of the phoslactomycin 
biosynthesis pathway follow the pathway shown in Figure 9, but confirmation of the 
proposed pathway is unknown28. In order to pave the way for the elucidation of the ordering 
steps of the post-polyketide synthase tailoring steps in the phoslactomycins pathway, we 
decided to study the functional role of the first proposed gene involved in the post-
polyketide synthase tailoring steps in vivo. 
Targeted gene replacement of post-PKS genes, provides a very useful tool for elucidation 
of the biosynthetic pathway, by analysis of accumulated intermediates or shunt products. 
Acquired knowledge from isolating and characterizing pathway intermediates can also be 
used in context of combinatorial biosynthesis to generate new unnatural natural products 
with potentially higher or altered biological activities30. A good example is the CYP450 
monooxygenase EpoK that catalyzes the final epoxidation step in epothilone A and B 
biosynthesis. Upon deletion of epoK, the resulting mutant stain accumulates epothilones C 
and D with epothilone D being most valuable antitumor due to increased therapeutic 
index31. It is possible that the opposite phenomenon can be observed, for example 
14 
 
biosynthesis gene inactivation in mithramycin, where gene inactivation led to the 
production of biologically inactive precursor premithramycin32. 
This chapter describes the isolation and partial structural elucidation of a new 
phoslactomycin intermediate (PLM 1) isolated from the culture broth of a plmT4 gene 
replacement mutant strain (named NP5) made from a mutant strain named NP2 (plmS2 
gene replacement mutant) a PLM B producing strain29. We report that in vivo plmT4 gene 
replacement leads to the accumulation of PLM 1, the earliest intermediate released from 
the phoslactomycin biosynthesis assembly line, supporting the proposed pathway in Figure 
9. PLM 1 was purified from various fractions by reverse phase HPLC to yield 0.12mg -
1mg and was partially characterized using a combination of spectroscopic analyses (MS, 
LC-MS and NMR) and the data obtained was consisted with the formation of the predicted 
PLM 1 compound.  
 
 
Figure 9. Proposed ordering of the post PKS tailoring steps in the PLM pathway 
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2.1 MATERIALS AND METHODS 
 
2.1.1Materials 
 
All chemicals and solvents were purchased from Sigma or Fisher and were of highest grade. 
Yeast extract, N-Z amine type A and beef extract were obtained from Difco. Yeast was 
generously given as a gift from Eli Lilly Scientific. Luria-Bertani (LB) capsules were 
purchased from Research Products International. 
2.1.2 Strain and Culture Conditions 
 
The NP2 mutant (∆plmS2, the control used as wild type) and the NP5 (∆plmT4∆plmS2) 
mutants were generated by Nadaraj Palaniappan using a gene deletion method. The strain 
was maintained on SY agar (1.0% soluble starch, 0.1% yeast extract, 0.1% N, Z Amine 
type A, (pH 7.0) for 7-14 days until the colonies appeared grayish in color. A seed culture 
was then prepared by inoculating 50mL of seed medium (3.0% soluble starch, 1.0% dried 
yeast, 0.3% NaCl, 0.3% CaCO3, pH 7.0) in a 500mL baffled flask with a loopful of spores. 
This culture was incubated at 28°C in the dark with shaking at 170 rpm for 48hrs. A second 
culture was then started using 1-1.5mL of the seed culture in 70mL of production medium 
(3.0% soluble starch, 1.0% dried yeast, 0.3% NaCl, 0.1% meat extract, 0.3% CaCO3, pH 
7.0) in a 500mL baffled flask and was incubated for 96 hours at 28°C in the dark with 
shaking at 170 rpm. To enhance production of naturally occurring PLMs or promote the 
production of novel compounds, the carboxylic acid form of the corresponding starter units 
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(cyclohexanecarboxylic acid 8-10mg per day )was dissolved in ethanol and were added to 
the production medium in four equal portions at 0, 24, 48 and 72 hours. At the end of the 
fermentation period, the mycelia were removed by centrifugation and the supernatant was 
subjected to further analysis and purification. 
2.1.3 Equipment 
 
Analytical and semi-preparative HPLC were performed using an Agilent 1100 HPLC 
system connected to a diode array detector. Samples were injected onto a 5µm Discovery 
HS C18 reverse phase column (4.6 x 250 mm, Supelco, Belefonte, PA) using a linear 
gradient from 0% to 60% between solvent A (acetonitrile: water; 20:80 with 0.05% formic 
acid) and solvent B (acetonitrile: water; 80:20 with 0.05% formic acid) over 40 minutes at 
a flow rate of 1.0 ml/min and detected at 235nm. Semi-preparative HPLC was performed 
using a 5µm Phenomenex C18 column (10.0 x 250 mm) under the same conditions except 
with a flow rate of 3.0 ml/min. Preparative HPLC was conducted with an Ascentis C18 
preparative column (Supelco, Belefonte, PA). Mass spectrometric analysis was carried out 
with a mass spectrometer (Bruker, Billerica, MA) utilizing electrospray ionization (ESI). 
4.0. LC-MS analysis was carried out using a linear gradient between solvent A (100% 
water, 0.1% formic acid) and solvent B (acetonitrile, 0.1% formic acid) from 20 to 60% 
over 30 minutes at a flow rate of 0.3 ml/min using an Agilent 1200 series HPLC equipped 
with an autosampler. The column used was a 5µm Discovery HS C18 reverse phase column 
(2.1 x 250 mm). All constant temperature incubations were done using an Innova 44 
incubator (±0.5°C, New Brunswick Scientific, Edison, NJ). 
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2.1.4 Analysis of NP5 Fermentation Broth 
 
To verify the presence of PLM products in the supernatant after fermentation, the 
fermentation broth was centrifuged and filtered (0.2 µL PTFE filter, Millipore Corp, MA). 
500µL of filtered broth was analyzed by analytical HPLC and PLM products were 
identified based on known retention times. The broth was injected onto a 5 μM Discovery 
HS C18 reverse phase column (4.6 x 250 mm, Supelco, Belefonte, PA) using a linear 
gradient described above and UV detection at 235 nm. 
2.1.5 Isolation and Purification of PLM 1 
 
Once production was confirmed, PLM products were extracted using XAD4 hydrophobic 
resin. The resin was first prepared by soaking in methanol overnight followed by a series 
of rinses with DI water. Approximately 300mL of broth was applied to 100mL of resin 
slurry and incubated with stirring at room temperature for 1 hour. The mixture was applied 
to a 250mL column and the run through was discarded. After washing the column with 1L 
of DI water, the PLM products were eluted using 300mL of methanol. The eluent, 
containing the active component was concentrated to dryness to give a brown residue. The 
residue was suspended in 10mL of methanol: water; 40:60 and filtered. This crude extract 
was purified by preparative or semi-preparative HPLC. Peaks corresponding to the various 
PLMs were collected and evaporated to dryness. 
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2.1.6 Characterization of PLM 1 
 
The identity and purity of the isolated compound was confirmed by HPLC, LC-MS, MS.  
1 H NMR was obtained for the isolated compound, to aid in the identification of the 
compound isolated proposed to be PLM 1. MS m/z 420 [M+NH4]
 + and 425 [M+Na] +. The 
data for 1 H NMR (chemical shifts and peaks) and for 1H- 1 HCOSY is shown in Figure 9 
and Figure 10 respectively. 
2.1.7 Preparation of Spore Suspension 
 
Spore suspension were prepared in 20% glycerol or 2YT media to maintain the NP5 
strain .The bacteria was allowed to grow and sporulate on SY agar for 14 days . 5mL of 
water or 2YT media was added to each plate. Using an inoculating loop, the spores were 
scraped off the plate and into suspension .The spore suspension was transferred using a 
biosterile pipette into a sterile tube with glycerol and stored at-800 C 
2.2 RESULTS AND DISCUSSlON  
 
Analysis of the PLM biosynthetic gene cluster indicated that there are three steps of 
hydroxylation ( at C-8,C-18 and C-25)  after the polyketide chain is released that likely 
involve the plmT4 and plmS2 genes, which encode proteins highly homologous to the 
cytochrome P450 monooxygenase. PlmS2 is responsible for catalyzing hydroxylation at C-
18 and hydroxylation at C-8 and C-25 are most likely catalyzed by PlmT4. To better 
understand the role of plmT4 gene in the PLM biosynthesis, the plmT4 gene was disrupted 
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(by a previous member of the group, Nadaraj Palaniappan) to block hydroxylation in the 
biosynthesis pathway. Using the fermentation and isolation method, the mutant strain, NP5 
(∆plmT4∆plmS2) was fermented along with the control NP2 (∆plmS2), a PLM B producing 
strain. Gene disruption of one of the tailoring enzymes, plmT4, not only results in the 
abolishment of the biosynthesis of PLM B, but also allows the accumulation of two 
intermediates, M-PLM1 and PLM 1 as shown in Figure 10.  HPLC analyses of the 
fermentation broth of this mutant reveled that as days increased, the M-PLM 1 disappeared 
and after four days only PLM-1 was observed as shown in Figure 10 (A, B and C). The 
malonylated lactone M-PLM 1 is unstable and undergoes decarboxylative elimination to 
give the corresponding PLM 1 as shown in Figure 11. PLM 1 was purified and identified 
using HPLC, MS and LC-MS spectroscopic analysis. HPLC and  LC-MS analysis of the 
purified compound revealed a peak eluting ~25.7 min (Figure 12  and Figure 13 ) also 
consistent with the correct mass of PLM 1 ([M+NH4]
+) = 420 and ([ M+Na]+) = 425). 
Comparison between the acquired mass and predicted mass for PLM 1 is as shown in 
Figure 14. The difference between the mass acquired for PLM 1, and the mass of the 
predicted molecular formula is only m/z 0.1505. A high resolution MS measurement for 
the compound was also consistent with a formula C25H38O4 for m/z 420 ([M+NH4]
 +) as 
shown in Figure 15. The results suggests that hydroxylation at C-8 and C-25 are the first 
steps in the process and catalyzed by the cytochrome P450 monooxygenase, encoded by 
plmT4. The formation of M-PLM1 from the mutant suggest that malonylation process must 
be occurring at an early stage , most likely preceding the release of the full length 
polyketide intermediate from PLM-PKS 
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                Figure 10. HPLC analysis of fermentation broth of NP5  
 
Figure 10. HPLC Analyses of fermentation broth of NP5 
 
 
 
 
                    Figure 11. Mechanism for decarboxylation of M-PLM 1 to PLM 1 
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Figure 12. HPLC analysis of purified PLM 1 from fermentation broth of NP5 
 
 
 
 
 
PLM 1 
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Figure 13. LC-MS analysis of purified PLM 1, m/z 420 and 425 
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Figure 14. Comparison between the acquired mass and predicted mass for PLM 1 
 
 
 
Figure 15. ES+ MS analysis of purified PLM 1, m/z 420 
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To further verify the structure of PLM, 1 H NMR of PLM 1 shown Figure 16 and 1H-1H 
COSY shown in Figure 17, were carried out. PLM B 1H NMR has been previously reported 
and was used in comparison with the isolated intermediate PLM 1. All of the typical peaks 
of the phoslactomycin polyketide were present, which suggesting some similarity with the 
isolated product. The difference between PLM 1 and PLM B is the functional group at C-
8 (OH in PLM B and H in PLM 1) and C 25 (NH2 in PLM B and CH3 in PLM 1). Most 
peaks were assigned by comparison with the spectra of the 1H NMR of PLMB. PLM 1 
spectrum was very similar to PLM-B except for the absorbance associated with a methyl 
proton at position C-25 and the proton at C-8. The new peak ( a triplet) appearing at 0.87 
ppm is assigned to the C-25 methyl protons.  The proton absorbance were  assigned using 
the 1H-NMR and the 1H-1H COSY with the most significant shift listed in Table 2. The 
assignment of vinyl protons at H-2 and H-3 indicates that the double bond alpha to the C-
l is present in PLM 1. Detailed analyses of the 1H-1H COSY NMR spectra data shown in 
Figure 17 also verified the polyketide structure by confirming the proton-proton 
correlations. The data shows key proton to proton coupling, linking C4 ,C5, C6, C7, C8, C9 
C10, C11 C12 and C13. The data also shows that protons on C8 are coupled to the protons at 
C24. Closer examination of the spectrun also reveals that the protons at C15 are coupled to 
the protons at C16. This data is consistent with the predicted PLM 1 intermediate. 
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Figure 16. 1H NMR of PLM 1 
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Table 1 1H NMR spectra data for PLM 1 
ppm Assignment 
7.09 3-H 
6.2~6.4 13, 14-H 
6.00 2-H 
5.72 7-H 
5.67 6-H 
5.33 15-H 
5.41 12-H 
5.11 5-H 
4.95 11-H 
3.90 9-H 
2.48~2.55 4-H, 16-H 
1.9 8-H 
1.0~1.8 24-H,22-H 
10-H, 17-H 
18-H, 19-H 
20-H, 21-H 
0.87~0.91 23-H and 25-H 
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Table 2 Comparison of 1 H-NMR chemical shifts for PLM 1and PLM B 
 
Assignment ppm PLM 1 ppm PLM B 
   
2-H 6.00 6.09 
3-H 7.09 7.09 
4-H 2.55 2.55 
5-H 5.11 5.11 
6-H 5.67 6.04 
7-H 5.72 5.97 
8-H 1.9 (OH group) 
9-H 3.90 4.28 
11-H 4.95 4.95 
12-H 5.41 5.41 
15-H 5.33 5.33 
13-H, 14-H 6.2~6.4 6.32~6.20 
16H 2.55 2.48 
23H 0.90 3.04 
25-H 0.87 3.00 
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Figure 17. 1H-1H COSY of PLM 1 (1) 
 
2.3 CONCLUSION 
 
Gene disruption of the tailoring enzyme encoded by plmT4 resulted in accumulation of 
compounds lacking C-8 and C-25 hydroxyl groups. Partial characterization of the isolated 
intermediate suggested that the plmT4 is likely to be responsible for C-8 and C-25 oxidation 
in the phoslactomycin biosynthesis. Further characterization is required using 2D-NMR 
techniques, to reveal carbon-carbon correlations and carbon-proton correlations. Together 
these results will support the proposed role of the plmT4 gene in the PLM biosynthesis. 
 
29 
 
CHAPTER 3. GENERATION OF A BLOCKED PM 1 MUTANT 
 
3.1 INTRODUCTION 
 
The biosynthetic gene cluster of phoslactomycin has been analyzed in detail by genetic and 
biochemical investigations and genes responsible for the synthesis of the phoslactomycin 
polyketide synthase have been cloned and sequenced. Studies showed that all PLM 
compounds were originating from a common CHC starter unit26. The sequence analysis of 
PLM biosynthetic gene cluster revealed the existence of a complete set of highly conserved 
genes responsible for the formation of CHC-CoA starter unit. Genes responsible for 
assembling the PLM carbon skeleton were identified and genes proposed to be involved in 
post-polyketide synthase tailoring steps were proposed for example, an oxidoreductase 
(plmT8) and aminotransferase (plmT1)28. The gene cluster also contains numerous other 
genes involved in regulation and resistance. The role of plmT8 has been proposed, but not 
experimentally determined. This chapter reports a genetic investigation of plmT8, and 
partial characterization of the mutant strain lacking a plmT8 gene, in order to confirm its 
role in the phoslactomycin biosynthetic pathway. 
The deletion or replacement of individual genes along a biosynthetic pathway can be used 
to probe the role of the genes in the biosynthesis in vivo33, 34. In this process, a particular 
gene can be completely deleted or replaced with another gene that confers resistance to a 
certain antibiotic such as ampicillin via PCR-targeted recombination or Red/ET-mediated 
recombination 7, 35. In this study, a plmT8 gene was replaced with an ampicillin resistance 
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marker. The cosmid 10B4 containing the partial phoslactomycin biosynthetic cluster was 
replaced in E coli by λRED-mediated recombination, creating a gene replacement. Gene 
replacement is an effective technique that takes advantage of the natural ability of an 
organism to recombine homologous regions of DNA34. A gene replacement generates a 
mutant inefficient or totally incapable of producing the natural product in question. The 
role of a gene in the biosynthesis of the natural product is found by analyzing and 
comparing the metabolite pool (intermediates or shunt metabolites) of the resultant mutant 
with the wild type35. The order of steps is then determined by ordering of mutants blocked 
at different steps within the pathway. This study paves the way for the elucidation of 
ordering steps of the phoslactomycin biosynthesis pathway by creating a plmT8 mutant 
strain (PM1) and partial characterization of generated compounds using mass spectroscopy. 
The plmT8 is proposed to be an oxidoreductase. The group of oxidoreductases comprises 
different types of enzymes such as oxygenases, oxidases, peroxidases, reductases and 
dehydrogenases23. To date various kinds of oxidoreductases are known, which are involved 
in post polyketide synthase tailoring steps23. These enzymes introduce oxygen-containing 
functionalities, such as hydroxyl, epoxide, aldehyde and keto groups, or modify these 
functionalities by adding or removing hydrogen atoms36. PlmT8 is proposed to catalyze 
oxidation of the C-25 OH group of PLM 1, a first step in introduction of amine function. 
Therefore the plmT8 mutant strain is expected to generate or accumulate PLM 2 
intermediate and other possible analogues as shown in Figure 18. The proposed post-PKS 
tailoring steps in phoslactomycin biosynthesis suggests that PLM 1 is the earliest 
intermediate, followed by PLM 2. 
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Figure 18. Proposed product of the plmT8 mutant 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Bacterial Strain, Plasmids and Reagents 
 
All chemicals and solvents were purchased from Sigma or Fisher and were of a highest 
grade. Yeast extract, N-Z amine type A and beef extract were obtained from Difco. Primers 
for PCR were purchased from Integrated DNA Technologies (Coralville, IA). Cosmid 
10B4 containing partial Streptomyces HK 803 genomic DNA and NP2 mutant strain were 
kindly provided by the previous member of the group. NP2 was the wild type PLM B 
producer used for generation of the PM1 mutant strain. DH5a was used as the host for 
standard cloning experiments. E. coli ET12567/pUZ8002 was used as cosmid donor host 
for E. coli-Streptomyces conjugation. E. coli BW25113/pIJ773 was provided by John Innes 
Center (Norwich, UK) as part of the REDIRECT Technology kit SuperCos1 (Stratagene). 
Platinum High Fidelity polymerase supermix was purchased from Invitrogen. All other 
X 
X 
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required reagents, including media, restriction enzymes, and other molecular biological 
reagents were acquired from standard commercial sources. 
3.2.2 Media and Culture Conditions 
 
E. coli strains were grown in Luria broth (LB) supplemented with antibiotics apramycin 
(50 μg/ml), chloramphenicol (25 μg/ml), and kanamycin (50 μg/ml) were added to the 
growth media as required. Soybean mannitol agar was used for maintaining NP2 and PM1 
mutant. Soybean mannitol agar supplemented with 50 μg/ml apramycin was used to 
maintain the exconjugants. All growth media for Streptomyces and E. coli were prepared 
according to standard protocols. 
3.3 GENERATION AND ANALYSIS OF PM 1 MUTANT 
 
3.3 1 DNA Manipulation and Construction of PM1 Mutant 
 
The NP2 (ΔplmS2) mutant (that produces only PLM B) from Streptomyces sp. HK 803 
strain was previously generated in our lab using a PCR-targeting based gene replacement 
method. The ΔplmT8 ΔplmS2 (PM1 mutant) was created from the NP2 (wild type strain), 
by replacing plmT8 with an aac(3)IV resistance marker and oriT cassette (which allows for 
efficient transfer to Streptomyces by RP4-mediated intergeneric conjugation). The 
replacement was first accomplished in cosmid 10B4 and subsequently in the chromosome 
of the NP2 mutant. Cosmid 1OB4 DNA was isolated from E. coli cells using QIAprep Spin 
Miniprep kit. In order to allow the integration of the 10B4 cosmid carrying the 
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phoslactomycin cluster into the genome of NP2 mutant, cosmid 10B4 was first transformed 
into E. coli BW25113/pIJ790 (recombination strain expressing λ-Red recombination 
functions)) via electroporation according to standard protocol. A gene replacement cassette 
containing aac (3)IV, oriT of RK2 and two FRT sites was amplified by using primers 
containing 39nt 5' homology extension corresponding to regions flanking the target gene 
and 20 nt-3' homology to the unique priming sites of the disruption cassette. Primer design 
and analysis was performed using MacVector (MacVector Inc., Cary, NC) and the forward 
primer: 5’-
CGGCCGCCCATGAAACGACTCGAAGGACGCAACGGCATGATTCCGGGATCCG
TCGACC-3’ and reverse primer 5’-
AGTGGYGTCGCCAACGGACGCGAACCGGCTCATGTAGGCTGGAGCTGCTTC-
3’were used (sequence homologous to the pIJ773 disruption cassette is shown in the   bold, 
italicized text).  The allelic replacement of the plmT8 gene in the NP2 was confirmed by 
PCR amplification. 
3.3 2 Production of PLM analogs 
 
The NP2 and PM1 mutants were maintained and grown in SY agar medium as shown in 
Figure 19. The production of phoslactomycin was carried out as previously described, were 
a loopful of spores was inoculated in 70 ml fermentation medium and incubated for 96 h 
at 28 oC with shaking at 170 rpm in the dark and at the end of the fermentation period, the 
cultures where harvested, the mycelia were removed by centrifugation, and the resulting 
supernatant was analyzed directly by HPLC, MS and LC-MS. 
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Figure 19. Growth of Streptomyces mutant strain PM1 on SY agar. Colonies appear 
slightly grayish in color 
 
3.3 3 HPLC and LC-MS analysis 
 
A 500 μL sample of the filtered supernatant of the fermentation broth was analyzed by 
using an Agilent 1100 HPLC system connected to a diode array detector. The PM broth 
was analyzed with 5 μm Discovery HS C18 reverse phase column (4.6x 250 mm, Supelco, 
Belefonte, PA) using a linear gradient between solvent A (acetonitrile: water; 20:80 with 
0.05% formic acid) and solvent B (acetonitrile: water; 80:20 with 0.05% formic acid) from 
0% to 60% over 40 minutes at a flow rate of 1.0 ml/min and detected at 235nm. The LC-
MS analysis was carried out using 100  of the supernatant under the same solvent and 
gradient conditions, with a flow rate of 0.3 ml/min using a Surveyor HPLC system 
(ThermoFinnigan) connected to a diode array detector equipped with a 2.1 μm Discovery 
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HS C18 reverse phase column (4.6 x 250 mm, Supelco). Mass spectra was collected on an 
LCQ quadrupole ion trap (ThermoFinnigan) mass spectrometer equipped with an 
electrospray ion source operating in positive mode. 
3.4 RESULTS AND DISCUSSION 
 
The replacement of the plmT8 gene was achieved through double crossover using 
REDIRECT technology. The target gene, which was identified on the 10B4 cosmid, was 
replaced by the aac(3)IV/oriT (red) cassette using PCR targeting strategies, yielding a 
mutated cosmid as shown in Figure 20. Figure 21, shows the PCR product of the amplified 
apramycin gene aac(3)IV oriT (red) cassette used to replace the targeted gene in the cosmid. 
The mutated cosmid was introduced into E.coli ET12567/pUZ8002 by electroporation and 
subsequently transferred into the target strain (NP2) by conjugation. The desired double 
crossover mutants, which were selected by their apramycin-resistant and kanamycin-
sensitive phenotype were isolated as PM1 (∆plmT8∆plmS2) and confirmed by PCR 
analysis as shown in Figure 22 (Lane 1and 2) and Lane 3-5 shows the control PCR (wild 
type NP2).  
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Figure 20. (A) Flow chart of gene disruption by PCR-targeting 
 
 
 
 
 
PCR product 
Wild type (NP2) 
 
 Streptomyces  
chromosome  
Mutant (PM1) 
Streptomyces 
chromosome  
1716 bp 
1353 bp 
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Figure 21. (A) Apramycin gene aac(3)IV/oriT (red) cassette 
 
 
 
 
 
 
 
 
 
 
Marker                      Marker      Lane         1              2 
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Figure 22. PCR confirmation analysis 
 
The PM1 (∆plmT8∆plmS2) mutant was fermented and processed along the wild. Analysis 
of fermentation broth revealed a peak eluting ~20.7 min in the total ion chromatogram (TIC) 
that had a m/z of 583 as shown in Figure 23, consistent with the formation of M-PLM 2 
([M-H+2Na]+). The addition of mild base to the PM1 fermentation broth resulted in the 
disappearance of this peak, consistent with our prediction of a malonylated product. 
Addition of a base will cause deprotonation of the malonyl group facilitating 
decarboxylative elimination reaction and the formation of corresponding product without 
 
Marker                Marker      Lane 1        2             3              4             5      
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a malonyl group. Analysis of the purified broth also revealed peaks with m/z 515 ([M+H] 
+), 532 ([M+NH4] +) and m/z 537 ([M+Na]
 +) as shown in Figure 24, consistent with the 
mass of the PLM 2 P compound. Analysis of the PM1 mutant also revealed a peak eluting 
at 6.2 min in the total ion chromatogram (TIC) that had a m/z of 453 and 475, consistent 
with the formation of PLM 2 with hydrolyzed lactone, ([M+H]+) and ([M+Na]+) 
respectively. A high resolution MS analysis of the filtered broth was consistent with 
formation of PLM 2 with a hydrolyzed lactone as shown in Figure 25. 
The observation of mass consistent with the formation of M-PLM 2, PLM 2 and PLM 2 P 
products in PM1 mutant suggests the proposed role of plmT8 as an oxidoreductase. The 
observation M-PLM 2 in the plmT8 deletion mutant strain  suggest that malonylation is 
likely to  occurs in the early stage, indicating that modification steps can occur on an 
intermediate with a C-3 malonyl group attached. Decarboxylation elimination by PlmT2 is 
likely to occur later in the post-PKS modification steps of phoslactomycin. The observation 
of phosphorylated products in the plmT8 mutant strain suggests that the proposed 
phosphorylation catalyzed by PlmT5 kinase can occur early in the step in the 
phoslactomycin pathway. The accumulation of PLM 2 products also supports that plmT4 
is responsible for addition of the C-8 and C-25 hydroxyl groups, since the mass obtained 
are consistent with oxidation at C-8 and C-25 (PLM 1). 
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Figure 23. LC-MS analysis of purified PM1 broth, m/z 583 
 
  
 
Figure 24. ES+ MS analysis of filtered of PM1 fermentation broth, 
 m/z 515, 532 and 537 
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Figure 25. ES+ MS analysis of filtered of PM1 fermentation broth, m/z 453 and 475 
 
Some of the key drawbacks to continued partial analysis include low fermentation titers 
and various analogues produced in the fermentation. Cloning of the PLM biosynthetic gene 
cluster and creation of a PM1 mutant sets the stage for isolation of the more gene product 
of the PM1 mutant and then NMR characterization will be possible. 
 
 
  
 
 
 
 
PM1B_131125142523 #1140 RT: 6.17 AV: 1 NL: 9.44E4
F: ITMS + p ESI Full ms [150.00-600.00]
160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580 600
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
475.25
172.75
453.25
213.75
186.08
476.25
171.00
163.75 459.33222.75204.67 352.08
526.08248.92 275.75 288.83 394.00326.83 361.50342.92 372.00305.00 417.00 491.08 537.00 582.25561.92509.00426.67 596.42
PLM 2+ H2O + H+    = 453 
PLM 2+ H2O+Na+ = 475 
42 
 
CHAPTER 4. HETEROLOGOUS EXPRESSION OF TAILORING ENZYMES 
 
4.1 INTRODUCTION  
 
The enzymological phase of polyketide biosynthesis research started in the 1990’s when 
the first crude cell extracts fractionations and in vitro characterizations were carried out. 
Amongst the first post-PKS tailoring enzymes to be isolated and studied was carminomycin 
4-O-methyltransferas37. It was partially purified from the wild type producer Streptomyces 
sp. strain37. In order to study and characterize individual enzymes participating in the 
biosynthesis of a polyketides, for example studying substrate specificity in vitro and a 
detailed kinetic analysis, their respective genes needs to be expressed in a heterologous 
host such as E.coli, followed by enzyme purification38. Successful production of proteins 
requires the success of three individual factors: expression, solubility and purification39. E. 
coli remains the most used host for recombinant protein expression because it is easy to 
manipulate and cheap40. A variety of high-level expression vectors are now available to 
allow gene expression under the influence of the bacteriophage T7 polymerase promoter41. 
The development of the His-Tag technology allows the fusion of six histidine amino acid 
residues to either the N- or C-terminal end of the expressed protein which facilitates the 
purification of the recombinant protein by affinity chromatography using metal chelation 
resins42. Additional residues or tags can be engineered on either N-terminal or C-terminal 
end of the protein of interest during cloning, tags can confer the advantage of increased 
yield, by providing a reliable context for efficient translation initiation, enhancing 
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solubility of expressed proteins42. A common limitation of recombinant protein production 
in bacteria is the formation of insoluble protein aggregates known as inclusion bodies. One 
possibility to avoid inclusion bodies is to use large affinity tags43. The biochemical features 
of different tags influence the stability, solubility and expression of proteins to which they 
are attached. In other words, using expression vectors that include a fusion tag facilitates 
recombinant protein solubility44. A disadvantage is, however, that proteins with these tags 
cannot be purified with a specific affinity matrix. The fusion construct must be used in 
combination with a small affinity tag for purification45. Elution of the bound enzyme is 
readily achieved by changing parameters such as salt concentration or pH.46 After 
purification, the proteins can be used in a number of assays depending on the reactions they 
catalyze to monitor the substrate specificity as well as the rate by which they catalyze their 
reactions. The in vitro assays using expressed enzymes provide greater and more valuable 
insight into the mechanistic role of the individual enzyme in the biosynthetic process as a 
whole. 
The final enzymes involved in phoslactomycin post-polyketide synthase tailoring steps 
have already been characterized. The enzymes studied are PlmT2, PlmS2 and PlmS3 as 
described in the introduction chapter and the enzymes were characterized by carrying out 
detailed in vitro enzyme assay. 
This chapter we describe the cloning, expression and purification of the initial post-PKS 
tailoring enzymes in the phoslactomycin biosynthesis. The proposed tailoring enzymes for 
this work in are, PlmT4 a cytochrome P450 monooxygenase, PlmT5 a kinase and PlmT8, 
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an oxidoreductase10. Expression and purification of these enzymes will pave the way for 
in vitro enzyme characterization methods and protein crystal structure determination (if 
needed) leading to analysis of the role of each proposed enzyme. This will lead the way for 
elucidation of the ordering steps of the post-polyketide synthase tailoring steps in the 
phoslactomycin pathway.  
 
 
Scheme 1. Proposed ordering of the post-PKS tailoring steps in PLM pathway 
 
The enzymes studied in this work, also commonly found occurring in post-PKS tailoring 
reactions are briefly discussed in the following section. 
4.1.1 Plm T4, a cytochrome P450 monooxygenase 
 
The plmT4 gene is proposed to be a cytochrome P450 monooxygenase. CYP450s belong 
to a very large and diverse family containing heme as a cofactor (hemeproteins). 
Cytochrome P450 (CYP450) proteins, named for the absorption band at 450 nm of their 
carbon monoxide bound form, are one of the largest superfamilies of enzyme proteins47. 
There is also a broad versatility of reactions catalyzed by cytochromes P450 such as carbon 
hydroxylation, heteroatom oxygenation, dealkylation, epoxidation, aromatic hydroxylation, 
45 
 
reduction, and dehalogenation48. In several instances, monooxygenases activity, arises 
from induction of CYP450 and associated ferredoxin or of a CYP450 only. CYP450 plays 
two main roles in living organisms namely catalyzing oxidation steps  in the biosynthesis 
of compounds like steroids and  detoxification of xenobiotics compounds, facilitating their 
elimination from living organisms49. CYPs have been proposed to be involved in the 
biosynthesis of phoslactomycin29. To date various kinds of CYPs, are known, which are 
involved in post-PKS modifications and understanding of CYP450 is essential for efficient 
engineering of Streptomyces strains capable of generating novel antibiotics. For example, 
approaches that utilize substrate promiscuity of CYP450s have been applied to generate 
novel analogues of erythromycin and pikromycin50. The proposed CYP-dependent 
hydroxylation (C-8, C-18 and C25) in the post-PKS tailoring steps of PLM, are proposed 
to be carried out by PlmS2 and PlmT4. The work on PlmS2 has already been completed and 
published by the previous member of the group, this work focus on cloning, expression, 
purification of PlmT4, and partial characterization of the enzyme (in vitro enzyme assay). 
 
4.1.2 Plm T5, a kinase 
 
A kinase is an enzyme that adds phosphate group to other molecules and these enzymes 
are key regulators of cell function51. Kinases which are involved in post-PKS modification 
have been studied, for example,  a kinase involved in the biosynthesis of a polyketide 
known as fostriecin25, 22.. Fostriecin is a unique phosphate monoester antibiotic that was 
isolated from Streptomyces pulveraceus and is structurally related to phoslactomycin52.  
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Homology analysis showed that fosH shares 43% sequence identity with PlmT5 and was a 
kinase, based on an enzyme activity assay performed in vitro. A FosH heterologous 
expression system was constructed on pET28b and introduced into E. coli BL21 to produce 
the target protein. The results obtained supported the hypothesis that FosH is responsible 
for the phosphorylation of fostriecin22. In this study we focused on cloning, expressing and 
purifying PlmT5, a putative kinase. This work will pave the way for in vitro enzyme assays 
so that the PlmT5 role in phoslactomycin biosynthetic pathway is confirmed. 
 
4.1.3 Plm T8, an oxidoreductase 
 
Several types of enzymes have been reported to be involved in post-PKS modifications 
catalyzing different chemical reactions28,53. The group of oxidoreductases comprises 
different types of enzymes such as oxygenases, oxidases, peroxidases, reductases and 
dehydrogenases36. These enzymes introduce oxygen-containing functionalities, such as 
epoxide, aldehyde and keto groups, or modify these functionalities by adding or removing 
hydrogen atoms, for example, transforming a ketone into a secondary alcohol or an 
aldehyde into a carboxylic acid36. All of these reactions have an impact on the stereo-
electronic and physico-chemical properties of the substrates, by creating or removing chiral 
centers, introducing highly reactive functional groups, such as aldehydes or epoxides, 
changing the solubility of a molecule or converting hydrogen bond donors. PlmT8 is 
proposed to transform the C-25 OH group into an aldehyde as shown in scheme 2 below.  
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Scheme 2. Proposed PlmT8 reaction 
4.2 MATERIALS AND NETHODS 
 
4.2.1 Materials  
 
Buffers, salts and reagents were of highest quality grade and were purchased from Sigma 
(St. Louis, MO) unless otherwise noted. Dithiothreitol (DTT), isopropyl-β-D-thiogalacto-
pyranoside (IPTG), kanamycin sulfate, β-NADPH (β- Nicotinamide adenine dinucleotide 
phosphate), β-NADP+ and ampicillin were purchased from RPI Corporation (Chicago, IL). 
Nickel-nitrilotriacetic acid agarose (Ni2+-NTA agarose) was purchased from Qiagen 
(Valencia, CA). Plasmid Mini-Kits were from Fermentas (Glen Burnie, MD). All reagents 
for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 10% 
acrylamide/Tris-HCl precast gels were purchased from BioRad. SDS-PAGE analysis was 
carried out using 12% gels and visualized with Coomassie Brilliant Blue. DNA sequencing 
was carried out at the DNA sequencing core facility at Oregon Health and Sciences 
University (OHSU), Portland, OR. The LIC cloning kits containing the pET44a plasmid 
was from Novagen. Restriction endonucleases and T4 DNA ligase was purchased from 
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New England Biolabs (Ipswich, MA). PCR primers were custom synthesized from 
Integrated DNA Technologies (Coralville, IA). PCR reactions were carried out with the 
GC Rich PCR System from Roche (Basel, Switzerland). 
4.2.2 Bacterial strains, plasmids, and growth conditions 
 
Luria-Bertani (LB) medium was used for growth of bacteria. The following antibiotics 
were added to the media when necessary: kanamycin (50 g/ml), carbenicillin (100 g/ml), 
chloramphenicol (20 g/ml), streptomycin (25 g/ml), and phleomycin (50 g/ ml). 
 
4.2.3 DNA manipulation 
 
DNA restriction and modifying enzymes were used as recommended by the manufacturer 
(New England Biolabs). Standard protocols were used for recombinant DNA techniques 
(Sambrook). DNA fragments were purified from agarose gels with the QIAquick 
purification kit (QIAGEN). Plasmids were prepared using a QIAprep spin miniprep kit 
(QIAGEN). Deep Vent DNA polymerase was used in all PCRs according to the supplier’s 
instructions (New England Biolabs). 
DNA sequencing was performed at the MMI core facility and at Primate Center, Oregon 
Health and Sciences University (Portland, OR). Primer design and analysis of DNA 
sequences was performed using MacVector (MacVector Inc., Cary, NC) and Accelrys DS 
gene (Accelrys Inc., San Diego, CA) software. 
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4.2.4 Instrumentation  
 
PCR was carried out on a Gene Amp PCR system 2400 from PerkinElmer Life Sciences. 
UV-Vis spectroscopy was performed with UV Shimadzu 1600. Centrifugation was carried 
out on an Avanti J- 20 centrifuge, an LE-80K Ultra centrifuge using a Ti-60 rotor, and a 
Model TJ 6 swinging bucket centrifuge, all from Beckman Coulter, Inc. SDS-PAGE was 
carried out on a mini Protean III from BioRad. 
 
4.2.5 Cloning, Expression and Purification of PlmT4 Protein 
 
The plmT4 gene was amplified from genomic DNA via PCR and cloned with either N- or 
C-terminal His6-fusions using the following primers forward primer 5’-
CATATGTCACAGCTCTCGTCC-3 and reverse primer, 5’-
AAGCTTTCACCACGTGACGGG-3’. The primers contained the restriction sites 
(underlined) for NdeI and HindIII to allow directional cloning into a pET28a vector. 
Amplification of the gene for construction of the N-terminal fusion was followed by 
restriction digestion of the PCR product with NdeI/HindIII, gel purification (1% agarose), 
and ligation into NdeI/HindIII digested pET28a using T4 DNA ligase to give pET28a-
plmT4. Plasmid DNA was isolated from all the constructs and the primary structure of the 
genes confirmed by sequencing. The plasmids containing plmT4 were transformed into E. 
coli BL21 (DE3) for expression of recombinant proteins. Cultures of transformed cells were 
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grown at 37 ˚C in LB/kan with shaking (250 rpm) until an OD600 of 0.9 was obtained, 
IPTG was added to a final concentration of 0.25 mM, and the cells were grown for an 
additional 4½ hours. The cells were collected by centrifugation at 7,500g for 15 minutes at 
4 ºC. The cells were stored at -80 ºC until needed. Frozen cell paste was suspended to 250 
mg/mL in 50 mM HEPES (pH 7.0), 0.75 M NaCl, 2 mM βME, and 1 mM PMSF. 
Lysozyme was added to a final concentration of 250 µg/mL and the cells incubated at 37 
˚C for 30 minutes, followed by 3 intervals of freeze thaw cycles. The cell lysate was 
centrifuged at 26,000g for 30 minutes at 4 ˚C, and the cell-free extract recovered and 
filtered (0.45 µm MCE). The CFE was loaded onto a column containing Ni2+-NTA agarose 
equilibrated in lysis buffer, and washed with 10 volumes of lysis buffer containing 25 mM 
imidazole. The protein was eluted with 250 mM imidazole in lysis buffer without. The 
eluant was concentrated to 2 mL using the Amicon Ultra YM-10. The fractions containing 
pure protein were pooled, exchanged with 50mM sodium phosphate buffer pH 7.2 and 
stored in 20% glycerol at -80 oC. 
  
4.2.6 Cloning, Expression and Purification of PlmT5 Protein 
 
The plmT5 gene corresponding to a kinase was amplified from genomic DNA via PCR and 
cloned with N –terminal using the following primer, forward primer 5’-
CATATGTATGTCGCCAAGTGC-3’ (NdeI restriction site) and reverse primer, 5’-
AAGCTTTCACTCGTACTGGCG-3’ (HindIII restriction site), Amplification of the gene 
for construction of the N-terminal fusion was followed by restriction digestion of the PCR 
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product with NdeI/HindIII, gel purification (1% agarose), and ligation into NdeI/HindIII 
digested pET28a using T4 DNA ligase to give pET28a-plmT5. The coding region of plmT5, 
was also amplified by primers were, 5’-GACGACGACAAGATGTATGTCGCCAA-3’, 
5’GAGGAGAAGCCCGGTCACTCGTACTG-3’.The 5’ end of the primer incorporated 
ligation-independent cloning (LIC) sequences. The amplified product was ligated into the 
vector pET-44 Ek/LIC after being treated with LIC-qualified T4 DNA polymerase. Primers 
for amplification of plmT5 were designed for subsequent LIC cloning in pET44a with an 
N-terminal NusA Tag. Amplification of the gene was followed by the insertion of the PCR 
products into pET44a following the manufacturer's instructions to give pET44-plmT5. To 
analyze expression of the plmT5 genes cloned in pET28a and pET44a, cultures of 
transformed BL21 (DE3) were grown overnight in tubes containing LB medium and 
appropriate antibiotics. Cultures were diluted 1:50 and grown at 37°C to mid-log phase 
(0.4 to 0.6 OD600 unit/ml). Gene expression was induced with 0.5 mM IPTG (isopropyl-
D-thiogalactopyranoside), and cultures were grown for 6 h at the same temperature. Cells 
were harvested by centrifugation at 12,000 g for 20 min, at 4 oC. The E. coli cell pellets 
were suspended in lysis buffer (50mM sodium phosphate buffer pH 7.2, 300mM NaCl, 
5mM 2-mercaptoethanol, 10% glycerol, 0.05% (v/v) Tween-20) with 10 mM imidazole 
and lysozyme (1 mg mL-1). The resulting cell suspension was incubated on ice for 30 min 
and cell lysate was cleared by centrifugation at 16,000 g for 20 min. For the protein cloned 
in pET28a, the crude cell extract was loaded onto a Ni-NTA resin column. His-tagged 
protein was eluted by using buffer-A with 300 mM imidazole. The purified protein was 
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analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
visualized by staining with Coomassie blue  
4.2.8 Cloning, Expression and Purification of PlmT8 Protein 
 
The gene plmT8 was amplified from 10B4 cosmid. To amplify plmT8, the following 
primers 5’-CATATGGCTAAGCGCTTCTCCACCATC-3’ (NdeI restriction site) and 
reverse primer, 5’-AAGCTTTCAGAGCTCGTGGTTCCGGAG-3’ (HindIII restriction 
site were used. The plm genes were cloned into expression vector pET28a to construct the 
plasmid pET28-plmT8. The plmT8 gene was also cloned into pET44 a vector using the 
same procedure described previously. The generated plasmids named pET-8a-plmT8 and 
pET-44-plmT8 were then transformed into E.coli strain BL21 (D3) cells and the positive 
clones were confirmed by DNA sequencing. All plasmids were used to transform E. coli 
BL21 (DE3) cells. The resulting transformants were grown at 37 oC in LB medium 
containing either 50 µg mL-1 kanamycin (for pET28a transformants) or 100 µg mL-1 
ampicillin (for pet44) to an A600 = 0.6, induced with 0.1mM isopropyl-β-D-
thiogalactopyranoside, and incubated overnight. Cells were harvested by centrifugation at 
12,000 g for 20 min, at 4 oC. The appropriate E. coli cell pellets were suspended in lysis 
buffer. A (50mM sodium phosphate buffer pH 7.2, 300mM NaCl, 5mM 2-
mercaptoethanol, 10% glycerol, 0.05% (v/v) Tween-20) with 10 mM imidazole and 
lysozyme (1 mg mL-1). The resulting cell suspension was incubated on ice for 30 min and 
cell lysate was cleared by centrifugation at 16,000 g for 20 min. The crude cell extract was 
loaded onto a Ni-NTA resin column. The PlmT8 protein was eluted by using buffer-A with 
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300 mM imidazole. Fractions containing pure protein were pooled, exchanged with 50 mM 
sodium phosphate buffer pH 7.2 and stored in 20% glycerol at -80 oC. 
4.2.9 Conversion of PLM 1 to PLM 2 in vitro 
 
The gene plmT4 encodes a cytochrome P450 monooxygenase (CYP450). The enzyme is 
likely to be responsible for C-8 and C-25 hydroxylation of the PLM PKS product. We 
believe that PLM 1,  is one the first intermediates and a substrate for PlmT4. Enzymatic 
conversion of PLM 1 to PLM 2 was be monitored by HPLC assy. The purified plmT4 (0.3 
μM) was incubated in a conversion buffer with PLM 1 (100 μM), spinach ferredoxin (50 
μg), ferredoxin NADP reductase (0.1 U), NADP (1 μmol), NADPH+ (1 μmol), glucose-6-
phosphate (10 μmol) and glucose-6-phosphate dehydrogenase (1 U) in a reaction volume 
of one ml at 30 oC for 30 minutes. NADP+, glucose-6-phosphate and glucose-6-phosphate 
dehydrogenase will be added as an “NADPH regenerating system. Simultaneous enzyme 
and substrate controls were run. An aliquot of reaction was be injected on HPLC to detect 
PLM 2 formation. The identity of PLM 2 was assayed by mass spectrometry. 
4.3 RESULTS AND DISCUSSION  
 
4.3.1 Characterization of the CYP450 in vitro by heterologous expression in E.coli 
 
To investigate the function of PlmT4 in the PLM biosynthesis pathway, an enzyme activity 
assay was performed in vitro.  First, a PlmT4 heterologous expression system was 
constructed on pET28a and introduced into E.coli BL 21 to produce target protein .The 
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expression plasmid was confirmed by sequencing and the target protein was purified as 
descried in the experimental procedures and analyzed by SDS-PAGE analysis. The SDS-
PAGE analysis revealed the presence of a significant quantity of a soluble protein of 46 
kDa (Figure 26 lane7-9), which was consistent with the predicted molecular mass of plmT4 
(44 kDa) and the hexahistidine tag (2 kDa). This band was absent in the control culture. 
PlmT4 was purified as a His-tagged protein by affinity chromatography on a Ni-NTA 
agarose column. The typical yields of purified PlmT4 were 408-600µg/mL. 
 
 
                   
 
 
 
 
 
 
 
 
 
 
 
Figure 26. (A) SDS-PAGE of purified PlmT4 protein 
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The eluted PlmT4 protein was brick red in color (Appendix Figure 34A). The term P450 is 
derived from the spectrophotometric peak at the wavelength of the absorption maximum 
of the enzyme (450nm) when it is in the reduced state and complexes with CO. The UV-
visible absorption spectrum of the spectrum of the purified protein shows a characteristic 
390 to 450nm CYP spectrum (Figure 27). The absorbance increased as the concentration 
of increased, as shown in Figure 27 
 
Figure 27. UV-Visible absorption spectrum of purified PlmT4 
 
[Increasing concentration]
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The recombinant PlmT4 was shown to catalyze a complete conversion of PLM 1 to PLM 
2 as shown in Figure 28. It is noteworthy that the hydrolyzed-PLM 2 product was observed 
under these reaction conditions, this lactone likely opens under basic conditions.  The MS 
for PLM 1 only is shown in Figure 29.  The likely identity of PLM 2 was assessed by MS 
and the analysis revealed that the new product, m/z of 453 and 475 as shown in Figure 30, 
consistent with the addition of two oxygen atoms to PLM 1. Control reaction is shown in 
Figure 31. This result supports the hypothesis that PlmT4 is likely to be responsible for the 
hydroxylation of C-8 and C-25. 
 
 
Figure 28. In vitro conversion of PLM 1 to PLM 2 
 
 
 
 
 
m/z, 441.24 and 425.27 m/z, 453.35 and 475.33
57 
 
 
 
 
Figure 29.  ES+ MS analysis of purified of PLM 1, m/z 425 and 441 
 
121913_131219133554 #10-55 RT: 0.07-0.43 AV: 46 NL: 1.10E8
T: FTMS + p ESI Full ms [200.00-1300.00]
400 410 420 430 440 450 460 470 480 490 500 510 520 530 540 550 560 570 580 590 600
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
441.24317
425.26925
491.30238
473.26913462.33554 597.34370
553.31721
444.24386
577.17669 591.39073487.28512 503.33907457.29533 541.30732 561.20271524.36154429.24319415.28498
497.23926
PLM 1+ Na+ = 425 
PLM 1 + K+ = 441 
58 
 
 
Figure 30. ES+ MS analysis of PLM 1 conversion reaction,m/z 453 and 475 
 
 
 
Figure 31. ES+ MS analysis of the enzyme control reaction (without enzyme), m/z 441 
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4.3.2 Purification of PlmT8 
 
The 1716 bp plmT8 ORF was cloned into prokaryotic expression vector pET28a and PlmT8 
was expressed as a soluble N-terminal polyhistidine tagged protein in E. coli 
ArcticExpressTM (DE3) cells. ArcticExpressTM competent cells are engineered to address 
the common bacterial gene expression hurdle of protein insolubility and competent cells 
have been engineered for improved protein processing at low temperatures. SDS-PAGE 
analysis of cell extracts grown under IPTG induction conditions revealed the presence of a 
significant quantity of a soluble protein of 62 kDa, which was consistent with the predicted 
molecular mass 61 kDa of PlmT8 (Figure 32 lane 7). This band was absent in the control 
culture. 
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Figure 32. SDS-PAGE of purified Plm T8 protein 
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contained a Nus-His-Tag of 57.8 kDa. With the fusion tag, the expressed plmT5 protein 
can be purified by either Ni2+ or S-protein affinity chromatography. Both Ni-NTA and S-
protein affinity chromatography were applied for the purification of pET44-plmT5. The 
size of the fusion matched well with its theoretical weight which is 88kDa (Lane 1). 
Meanwhile the pET-44-plmT5 was also engineered to express an enterokinase and a 
thrombin cleavage site so that the encoded fusion sequence can be removed from the 
purified PlmT5 protein The target protein PlmT5 was easily released from S-protein agarose 
following digestion with a substantial quantity of thrombin, which appeared as a single 
band on SDS-PAGE with a mass consistent with the theoretical weight of 25 kDa as shown 
in Figure 33 (lane 4- 6) 
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Figure 33. SDS-PAGE of purified Plm T5 protein 
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CHAPTER 5. CONCLUSION AND FUTURE DIRECTION 
 
5.0 CONCLUSION AND RECOMMENDATION FOR FUTURE WORK 
 
The phoslactomycin gene cluster consists of 29 ORFs encoding seven modular type 1 
polyketide designated (plm1 through plm 7) and tailoring enzymes28. Structurally, the 
natural phoslactomycin has varying functionalities that are absent from the molecule 
generated from PKS, including three hydroxyl groups at C-8 and C-18 positions, a 
phosphoryl group at C-9, an amine group at C-25 and an unsaturated bond at the C2-C3 
site. After PKS elongation and liberation from PKS by the TE enzyme, the nascent PKS 
chain undergoes some or all of the normal post-polyketide synthase tailoring steps that are 
typically associated with phoslactomycin natural product such as hydroxylation, 
phosphorylation and others. The work presented in this thesis describes the initial post-
PKS tailoring steps in the biosynthesis of phoslactomycin. It also provides valuable insights 
into the in vivo roles of key enzymes involved in the biosynthesis of phoslactomycin. 
The first steps of the post-PKS tailoring steps in the phoslactomycin pathway were 
analyzed using in vivo or in vitro analyses of selected genes by targeted gene replacement 
and enzyme activity assays. The observation of M-PLM 1 and M-PLM 2 from the plmT4 
and plmT8 deletion mutants suggest that the malonic acid is linked to the PKS chain at the 
last module of plm cluster (module 7) during PKS elongation, most likely it precedes the 
release of the full length polyketide intermediate from PLM-PKS. The observation of 
malonylated products also suggests that modification steps can occur on an intermediate 
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with a C-3 malonyl group on it, suggesting that decarboxylation elimination by PlmT2 is 
likely to occur later in the post-PKS modification steps of phoslactomycin. The cis-∆2, 3 
double bond formation might even be the last step in the post-PKS tailoring of 
phoslactomycin biosynthesis to yield phoslactomycin. At this point, when or how the 
malonylation occurs in the PLM biosynthetic process remains a mystery. Future work is 
required to unveil this mystery. 
The isolation of PLM 1 from the plmT4 mutant strain indicates that PLM 1 is likely to be 
the first intermediate and a substrate of PlmT4 enzyme. This enzyme is the only other P450 
monooxygenase encoded by the phoslactomycin biosynthetic gene cluster. Based on gene 
replacement and in vitro enzyme activity assay, Plm T4 is likely to be responsible for C-8 
and C-25 hydroxylation of the PLM-PKS product. Further characterization of the isolated 
intermediate is needed using spectroscopic analyses such as 2D NMR to further confirm 
the linking of carbon to carbon bonds and carbon to protons bonds. For example the 2D 
HSQCED spectra of PLM 1 will confirm how the protons are attached to carbons. PLMs 
were first identified based on their potent antifungal activity against a range of 
phytopathogenic fun. The potent activity of the isolated intermediate PLM 1 can also be 
tested. Activities against Aspergillus oryzae, Pyricularia oryzaei and Aspergillus fumigatus 
is worth reporting in future. 
The accumulation of the several PLM 2 products in the plmT8 mutant strain suggested that 
plmT8 gene is likely to be responsible for the oxidation of the C-25 hydroxyl group to the 
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corresponding aldehyde. Further work includes isolating the observed intermediates and 
characterization using NMR and carrying out in vitro enzyme assays.  
The observation of phosphorylated products in the plmT8 mutant strain suggests that the 
proposed phosphorylation catalyzed by PlmT5 kinase can occur early in the step in the 
phoslactomycin pathway. Future work includes studying and analyzing the product profile 
of the plmT5 mutant strain to further analyze the stage at which phosphorylation occur in 
the pathway. 
The tailoring enzymes expressed and purified in this study also sets the stage for 
determining the ordering steps of the post-PKS tailoring steps. The enzyme are used for 
characterization of the pathway by carrying out detailed in vitro enzyme assays, like 
determining reaction rates of isolated intermediate with proposed substrates, understanding 
and analyzing substrate specificity as well. Other studies that can be done using the 
enzymes if necessary is carrying out x-ray crystallography. This will provide a more 
comprehensive understanding of the interaction of proteins with the substrates. Tailoring 
enzymes also presents another variable that can impact structural diversity in modular PKS. 
So studying the enzymes may offer an opportunity to modify the structure of existing 
natural product based drugs to improve their activity, stability and pharmacokinetic 
properties.  
The results obtained in this study pave the way for the complete elucidation of the post-
PKS tailoring steps in the phoslactomycin biosynthesis pathway. It is worth mentioning 
that the ordering steps may not be absolute, there may be parallel pathways, and for 
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example phosphorylation and decarboxylation elimination may occur on several 
intermediates. The data obtained in this study sets the stage for understanding the 
mechanisms that build these structurally unique and pharmaceutically important agents and 
contributes to the general field of combinatorial biosynthesis.  
.  
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7.0 APPENDIX 
 
 
 
Figure 34 A. Purified PlmT4 protein 
  
